We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00002175
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NIH AIDS Clinical Trials Information Service
  Purpose
To evaluate the efficacy of dinitrochlorobenzene (DNCB) in patients with early HIV infection by monitoring immunologic parameters and serum HIV RNA. To facilitate the understanding of possible alterations in the immunological status of the HIV+ patient cohort.

Condition Intervention Phase
HIV Infections Drug: Dinitrochlorobenzene Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

Resource links provided by NLM:


Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment: 46
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

Patients must have:

  • EITHER HIV negative or documented HIV+ by both the ELISA and Western blot tests.

For HIV+ patients:

  • Patients must fail to meet the AIDS-defining criteria.
  • CD4 lymphocyte count between 200 - 500 cells/mm3.

Exclusion Criteria

Co-existing Condition:

Excluded:

Patients with obvious ultra violet(UV)-irradiated skin damage in the treatment sites.

Concurrent Medication:

Excluded:

  • Patients who are likely to commence antiretrovirals within the 6-month study period.
  • Patients using other immunomodulator therapies or other alternative therapies.
  • Patients likely to require chemotherapy during the course of the study.

Concurrent Treatment:

Excluded:

  • Patients who are likely to require significant UV light exposure during the study period.
  • Patients who are likely to require radiation therapy during the course of the study.

Prior Medication:

Excluded:

  • Prior exposure to DNCB.
  • Patients who have used antiretroviral medications within the previous 3 months.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002175


Locations
United States, Hawaii
Queen Emma Clinics / The Queen's Med Ctr
Honolulu, Hawaii, United States, 96813
Sponsors and Collaborators
The Honolulu Medical Group
  More Information

ClinicalTrials.gov Identifier: NCT00002175     History of Changes
Other Study ID Numbers: 265A
First Submitted: November 2, 1999
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
Last Verified: January 1999

Keywords provided by NIH AIDS Clinical Trials Information Service:
Cohort Studies
RNA, Viral
Administration, Cutaneous
Anti-HIV Agents
Dinitrobenzenes

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases